Cross-sectional assessment of three commonly used measures of adherence to combination antiviral therapy in a resource limited setting

Abstract

Nowadays, global coverage of combination antiretroviral therapy (cART) has increased due to a continuous process to scale up access. This increase has potentially transformed HIV-infection from a fatal to a chronic disease: a transformation only possible if the prescribed medications are taken accordingly. We therefore evaluated optimal adherence to cART by three commonly used methods: visual analogue scale (VAS), four days recall (FDR) and clinic attendance (CA) for the last six months in 301 HIV-infected patients on cART for at least six months at the Douala General Hospital, Cameroon. Optimal adherence was defined to be greater than or equal to the 95th percentile estimate of each method. We found that 70.8% of our study population was female. The mean age was 40.8 years (SD 10.5) and 85% were on first line cART. Median CD4 count was 397 cells/ml (252–559). Optimal adherence by VAS, FDR and CA, was 68.1%, 83.4%, and 73.4%, respectively. VAS and FDR inter-correlated strongly (Pearson’s Chi square coefficient, r = 0.58, p < 0.001). Higher CD4 count above 200 cells/ml was associated with optimal adherence by CA (Adjusted Odds Ratio [AOR]:2.6 (95% CI: 1.2–5.3, p < 0.001)). As high optimal adherence to cART is associated with good clinical outcome in HIV patients, simple methods such as the VAS for evaluating adherence, should be integrated to the HIV clinic of the Douala General Hospital.

Keywords

Adherence visual analogue scale four day recall clinic attendance

Get full access to this article

View all access options for this article.

References

Global Health Observatory (GHO) data. Number of people (all ages) living with HIV 2013, http://www.who.int/gho/hiv/epidemic_status/cases_all_text/en/ (2015 accessed 10 February 2015).

Data, W.L.C.-i.-P. Global update on HIV treatment 2013: results, impact and opportunities, http://www.unaids.org/sites/default/files/media_asset/20130630_treatment_report_en_0.pdf (2013).

Palella

Jr. . Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New Engl J Med 1998; 338: 853–860.

Bozzette

. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. New Engl J Med 1998; 339: 1897–1904.

Hecht

. Measuring HIV treatment adherence in clinical practice. AIDS Clin Care 1998; 10: 57–59.

McNabb

. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis: an official publication of the Infectious Diseases Society of America 2001; 33: 700–705.

Mannheimer

. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis: an official publication of the Infectious Diseases Society of America 2002; 34: 1115–1121.

Carmona A, Knobel H and Guelar A. Factors influencing survival in HIV infected patients treated with HAART. In: Program and abstracts of the XIIIth international AIDS conference, Durban, South Africa, 2000.

Hogg R, et al. Non-adherence to triple combination therapy is predictive of AIDS progression and death in HIV-positive men and women. In: Program and abstracts of the XIIIth International AIDS conference, Durban, South Africa, 2000.

10.

Carter M, ed. Adherence – information series for HIV-positive people people. 3rd ed. 2005. London: NAM.

11.

Arnsten

. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis: an official publication of the Infectious Diseases Society of America 2001; 33: 1417–1423.

12.

Paterson

. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21–30.

13.

Bartlett

. International HIV workshop on management of treatment-experienced patients. Hopkins HIV Rep: a bimonthly newsletter for healthcare providers/Johns Hopkins University AIDS Service 2002; 14: 4–5.

14.

Vitolins

. Measuring adherence to behavioral and medical interventions. Control Clin Trial 2000; 21: 188S–194S.

15.

Simoni

. Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav 2006; 10: 227–245.

16.

Marcellin

. Assessing adherence to antiretroviral therapy in randomized HIV clinical trials: a review of currently used methods. Expert Rev Anti-infect Ther 2013; 11: 239–250.

17.

Martin

. A comparison of adherence assessment methods utilized in the United States: perspectives of researchers, HIV-infected children, and their caregivers. AIDS Patient Care STDs 2009; 23: 593–601.

18.

Amberbir

. Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia. BMC Public Health 2008; 8: 265–265.

19.

Cauldbeck

. Adherence to anti-retroviral therapy among HIV patients in Bangalore, India. AIDS Res Ther 2009; 6: 7–7.

20.

Harrigan

. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191: 339–347.

21.

Sethi

. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis: an official publication of the Infectious Diseases Society of America 2003; 37: 1112–1118.

22.

DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Developed by the Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents – A working Group of the Office of AIDS Research Advisory Council (OARAC). 2014.

23.

Pefura-Yone

. Non-adherence to antiretroviral therapy in Yaounde: prevalence, determinants and the concordance of two screening criteria. J Infect Public Health 2013; 6: 307–315.

24.

Roux

. Adherence to antiretroviral treatment in HIV-positive patients in the Cameroon context: promoting the use of medication reminder methods. J Acquir Immune Defic Syndr 2011; 57: S40–S43.

25.

Mbopi-Keou

Dempouo Djomassi

Monebenimp

. Study of factors related to adherence to antiretroviral therapy among patients followed at HIV/AIDS Unit in the District Hospital of Dschang, Cameroon. Pan African Med J 2012; 12: 55–55.

26.

Giordano

. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trial 2004; 5: 74–79.

27.

Ferradini

. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006; 367: 1335–1342.

28.

Coetzee

. Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa. AIDS 2004; 18: S27–S31.

29.

Walsh

Mandalia

Gazzard

. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 2002; 16: 269–277.

30.

Oyugi

. Multiple validated measures of adherence indicate high levels of adherence to genericHIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr 2004; 36: 1100–1102.

31.

Amico

. Visual analog scale of ART adherence: association with 3-day self-report and adherence barriers. J Acquir Immune Defic Syndr 2006; 42: 455–459.

32.

Mahy

. Measure of effectiveness and adherence to antiretroviral therapy in HIV-infected patients in Cameroon. Medecine et maladies infectieuses 2011; 41: 176–180.

33.

Joslyn

. Memory for memory. Memory Cognition 2001; 29: 789–797.

34.

Yaya

. Predictors of adherence to antiretroviral therapy among people living with HIV and AIDS at the regional hospital of Sokode, Togo. BMC Public Health 2014; 14: 1308–1308.

35.

Kunutsor

. Improving adherence to antiretroviral therapy in sub-Saharan African HIV-positive populations: an enhanced adherence package. AIDS Care 2012; 24: 1308–1315.

36.

Sangeda

. Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settings. BMC Public Health 2014; 14: 1035–1035.

37.

Mee

. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008; 22: 1971–1977.

38.

Phillips

. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 2008; 371: 1443–1451.

39.

Chesney

. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000; 12: 255–266.